Invitrogen Corporation has announced the introduction of its Invivofectamine delivery reagent that enables short interference ribonucleic acid (SiRNA) experiments in vivo.
The study of RNA interference has revolutionised biology by allowing researchers to directly observe the effects of the loss of function of specific genes in mammalian systems.
The Invivofectamine delivery reagent allows researchers to directly study the effects of SiRNA inside a living organism for a variety of applications, including the drug discovery process.
'The Invivofectamine reagent is a breakthrough for the development of RNAI applications in animals that could lead to the rapid discovery of new therapeutic solutions for diseases such as cancer and metabolic diseases,' said Charles Piazza, vice president and general manager of Invitrogen's molecular biology.
'Invivofectamine reagent gives customers the ability to perform in vivo RNAI experiments that have so far been difficult to perform.' Invivofectamine delivery reagent can be injected in small volumes and without high pressure, minimising the potential of inconsistent results.
It also provides extra stability to SiRNA so the SiRNA will arrive intact and ready to perform the selected knockdown.
The reagent is non-viral and has minimal toxicity.
